LATTICE BIOLOGICS LTD. ANNOUNCES CHANGE IN DIRECTOR AND CHAIRMAN OF SCIENTIFIC ADVISORY BOARD

July 06, 2017 02:00 PM Mountain Daylight Time

BELGRADE, Mont.–(BUSINESS WIRE)–Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) (“Lattice Biologics” or the “Company”) announces a change in its Board of Directors and appointment of Chairman of the Scientific Advisory Board.

After a successful annual general and special meeting (AGM), and a nomination to the Board of Directors on June 30, 2017, the Company is pleased to announce the addition of Kevin Loud to the Board of Directors.

All resolutions of the AGM passed with more than 99% voting shareholder approval, including; election of directors, appointment of MNP LLP as auditors, settlement of accrued officer compensation, creation of new control person, approval of stock option plan and amendment to the Company’s articles.

“It’s an honor to be elected to the Board of Directors of Lattice Biologics. The Company is a true visionary in the use of biologics and is on the forefront of regenerative medicine. I look forward to contributing my efforts to assist the Company in its continued success,” states Loud.

Board of Director, Cathy Thomas, resigned her position effective June 26, 2017, due to conflicting time priorities. “We appreciate Cathy’s time and dedication, and wish her the best in the future,” states Guy Cook, CEO.

The Company is also pleased to announce the addition of Dr. Kerry Zang to act as its Chair of the Scientific Advisory Board. “My becoming involved with Lattice Biologics has been a game changer for me. Regenerative medicine allows me the opportunity to treat patients in a proactive, not reactive manner. Having the potential to repair and restore rather than to remove and replace, or just to control symptoms, is most gratifying. It’s really what medicine should be,” states Zang.

Cook states, “I’m delighted with the appointments of two such influential directors. Kevin Loud has raised over $7 million for the Company, and continues to bring his strong financial skills to help Lattice accomplish its goals. Dr. Zang is an early adopter of the amniotic fluid technology, and has seen excellent results for his patients. Dr. Zang is a world renowned key opinion leader in the space, and we are honored to have his experience and guidance in directing clinical efforts.


 

Subscribe to Lattice News Updates
Follow us on Twitter: @LatticeBio

About Lattice Biologics Ltd.:

Lattice Biologics Ltd. is an emerging precision medicine leader in the field of cellular therapies and tissue engineering, with an emphasis on bone, skin, and cartilage regeneration. As a manufacturer of the highest quality allografts, Lattice is focused on next generation products to improve surgical outcomes.

Lattice Biologics operates headquarters, laboratory and manufacturing facilities in Belgrade, Montana as well as offices in Toronto Ontario. The Company maintains all necessary licensures to process and sell its tissue engineered products within the U.S. and internationally. This includes Certificates to Foreign Governments from the U.S. Food and Drug Administration (FDA) and registrations for 29 countries, which allow the export of bone, tendon, meniscus, ligament, soft tissue, and cartilage products outside of the U.S.

Lattice Biologics (TSX-V: LBL) (OTCQB: LBLTF) became a publicly traded company on January 4, 2016.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts
Lattice Biologics Ltd.
Cheryl Farmer, 480-563-0800
CFO
News@LatticeBiologics.com
www.LatticeBiologics.com